These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28611859)

  • 41. SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.
    Tahara A; Takasu T
    Physiol Rep; 2019 Nov; 7(22):e14286. PubMed ID: 31782258
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus.
    Bando Y; Ogawa A; Ishikura K; Kanehara H; Hisada A; Notumata K; Okafuji K; Toya D
    Diabetol Int; 2017 Jun; 8(2):218-227. PubMed ID: 30603325
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Prospective, Open-Label Short-Term Pilot Study on Modification of the Skin Hydration Status During Treatment With a Sodium-Glucose Cotransporter-2 Inhibitor.
    Tezuka Y; Sekine O; Hirano A; Hanada Y; Nakanishi I; Ariga M; Azuma C; Yamamoto Y; Ito-Kobayashi J; Washiyama M; Iwanishi M; Furuta M; Kanamori M; Shimatsu A; Kashiwagi A
    Diabetes Ther; 2021 Jan; 12(1):431-440. PubMed ID: 33108650
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus.
    Bando Y; Tohyama H; Aoki K; Kanehara H; Hisada A; Okafuji K; Toya D
    J Clin Transl Endocrinol; 2016 Dec; 6():1-7. PubMed ID: 29067237
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM.
    Nakamura I; Maegawa H; Tobe K; Uno S
    Diabetes Ther; 2021 May; 12(5):1359-1378. PubMed ID: 33730336
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Exercise is associated with metabolism regulation and complications in Korean patients with type 2 diabetes.
    Noh JW; Park JE; Jung JH; Lee JH; Sim KH; Kim MH
    J Phys Ther Sci; 2015 Jul; 27(7):2189-93. PubMed ID: 26311952
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparing the efficacy of apple peels and a sodium-glucose cotransporter 2 inhibitor (ipragliflozin) on interstitial glucose levels: A pilot case study.
    Okada J; Yamada E; Okada K; Okada S; Yamada M
    Curr Ther Res Clin Exp; 2020; 93():100597. PubMed ID: 32874375
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of Luseogliflozin on Vaginal Bacterial and Fungal Populations in Japanese Patients With Type 2 Diabetes.
    Kusunoki M; Tsutsumi K; Wakazono N; Hisano F; Miyata T
    J Clin Med Res; 2021 May; 13(5):309-316. PubMed ID: 34104283
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical response to sodium glucose co-transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma.
    Izumi K; Iimura Y; Hiruma K; Touma T; Tsukamoto T
    IJU Case Rep; 2019 Sep; 2(5):269-271. PubMed ID: 32743434
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
    Iizuka T; Iemitsu K; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Kawata T; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 Mar; 8(3):267. PubMed ID: 26858805
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correction to: Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM.
    Nakamura I; Maegawa H; Tobe K; Uno S
    Diabetes Ther; 2021 Oct; 12(10):2801-2805. PubMed ID: 34463953
    [No Abstract]   [Full Text] [Related]  

  • 52. Correction to: Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM.
    Nakamura I; Maegawa H; Tobe K; Uno S
    Diabetes Ther; 2021 Jun; 12(6):1765-1768. PubMed ID: 34018149
    [No Abstract]   [Full Text] [Related]  

  • 53. Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study.
    Fukuda T; Bouchi R; Terashima M; Sasahara Y; Asakawa M; Takeuchi T; Nakano Y; Murakami M; Minami I; Izumiyama H; Hashimoto K; Yoshimoto T; Ogawa Y
    Diabetes Ther; 2017 Aug; 8(4):851-861. PubMed ID: 28616806
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.
    Osonoi T; Nakamoto S; Saito M; Tamasawa A; Ishida H; Osonoi Y
    J Diabetes Investig; 2018 Mar; 9(2):341-353. PubMed ID: 28644562
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations With Baseline Data.
    Yanai H; Hakoshima M; Adachi H; Kawaguchi A; Waragai Y; Harigae T; Masui Y; Kakuta K; Hamasaki H; Katsuyama H; Kaga T; Sako A
    J Clin Med Res; 2017 Jul; 9(7):605-612. PubMed ID: 28611861
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.
    Januzzi JL; Butler J; Jarolim P; Sattar N; Vijapurkar U; Desai M; Davies MJ
    J Am Coll Cardiol; 2017 Aug; 70(6):704-712. PubMed ID: 28619659
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.
    Iemitsu K; Kawata T; Iizuka T; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyanagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2017 Sep; 9(9):793-801. PubMed ID: 28811858
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
    Kaneko M; Narukawa M
    Ann Pharmacother; 2017 Jul; 51(7):570-576. PubMed ID: 28622738
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes.
    Ohta A; Kato H; Ishii S; Sasaki Y; Nakamura Y; Nakagawa T; Nagai Y; Tanaka Y
    Expert Opin Pharmacother; 2017 Oct; 18(14):1433-1438. PubMed ID: 28770629
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.
    Ito D; Shimizu S; Inoue K; Saito D; Yanagisawa M; Inukai K; Akiyama Y; Morimoto Y; Noda M; Shimada A
    Diabetes Care; 2017 Oct; 40(10):1364-1372. PubMed ID: 28751548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.